Aprea Therapeutics (APRE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

APRE Stock Forecast

Aprea Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

APRE Analyst Ratings

Buy

According to 7 Wall Street analysts, Aprea Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for APRE stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 2 'Hold' (28.57%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Mar 10, 2023	Loop Capital Markets	-	Buy	Initialise
Mar 10, 2023	Citigroup	-	Buy	Initialise
Mar 10, 2023	RBC Capital	-	Outperform	Initialise
Mar 10, 2023	Cowen & Co.	-	Market Perform	Initialise
Mar 10, 2023	UBS	-	Sell	Initialise
Jul 08, 2022	Wedbush	-	Outperform	Initialise
Dec 29, 2020	Morgan Stanley	Equal-Weight	Equal-Weight	Hold

Row per page

Go to

Aprea Therapeutics's last stock rating was published by Loop Capital Markets on Mar 10, 2023. The company Initialise its APRE rating from "null" to "Buy".

Aprea Therapeutics Financial Forecast

Aprea Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23
Revenue	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	$250.00K	$225.00K	$50.00K	$165.00K	$125.00K
High Forecast	-	-	-	-	$250.00K	$225.00K	$50.00K	$165.00K	$125.00K
Low Forecast	-	-	-	-	$250.00K	$225.00K	$50.00K	$165.00K	$125.00K
# Analysts	-	-	-	-	1	1	1	2	1
Surprise %	-	-	-	-	-	-	-	-	-

Aprea Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. APRE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Aprea Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23
# Analysts	-	-	-	-	1	1	1	2	1
EBITDA	-	-	-	-	-	-	-	-	$-3.52M
Avg Forecast	-	-	-	-	$150.00K	$135.00K	$30.00K	$99.00K	$75.00K
High Forecast	-	-	-	-	$150.00K	$135.00K	$30.00K	$99.00K	$75.00K
Low Forecast	-	-	-	-	$150.00K	$135.00K	$30.00K	$99.00K	$75.00K
Surprise %	-	-	-	-	-	-	-	-	-46.97%

undefined analysts predict APRE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aprea Therapeutics's previous annual EBITDA (undefined) of $NaN.

Aprea Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23
# Analysts	-	-	-	-	1	1	1	2	1
Net Income	-	-	-	-	-	-	-	-	$-3.20M
Avg Forecast	$-2.64M	$-2.52M	$-2.32M	$-4.10M	$-3.98M	$-4.26M	$-3.66M	$-4.55M	$-6.69M
High Forecast	$-2.64M	$-2.52M	$-2.32M	$-4.10M	$-3.29M	$-4.26M	$-3.66M	$-1.55M	$-6.69M
Low Forecast	$-2.64M	$-2.52M	$-2.32M	$-4.10M	$-4.67M	$-4.26M	$-3.66M	$-7.56M	$-6.69M
Surprise %	-	-	-	-	-	-	-	-	0.48%

Aprea Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. APRE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aprea Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23
# Analysts	-	-	-	-	1	1	1	2	1
SG&A	-	-	-	-	-	-	-	-	$1.72M
Avg Forecast	-	-	-	-	$921.90K	$829.71K	$184.38K	$608.45K	$460.95K
High Forecast	-	-	-	-	$921.90K	$829.71K	$184.38K	$608.45K	$460.95K
Low Forecast	-	-	-	-	$921.90K	$829.71K	$184.38K	$608.45K	$460.95K
Surprise %	-	-	-	-	-	-	-	-	3.73%

Aprea Therapeutics's average Quarter SG&A projection for Dec 23 is $608.45K, based on 2 Wall Street analysts, with a range of $608.45K to $608.45K. The forecast indicates a -64.62% fall compared to APRE last annual SG&A of $1.72M (Sep 23).

Aprea Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23
# Analysts	-	-	-	-	1	1	1	2	1
EPS	-	-	-	-	-	-	-	-	$-0.86
Avg Forecast	$-0.45	$-0.42	$-0.39	$-0.69	$-0.67	$-0.72	$-0.62	$-0.77	$-1.13
High Forecast	$-0.45	$-0.42	$-0.39	$-0.69	$-0.55	$-0.72	$-0.62	$-0.26	$-1.13
Low Forecast	$-0.45	$-0.42	$-0.39	$-0.69	$-0.79	$-0.72	$-0.62	$-1.27	$-1.13
Surprise %	-	-	-	-	-	-	-	-	0.76%

According to undefined Wall Street analysts, Aprea Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to APRE previous annual EPS of $NaN (undefined).

Aprea Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
LUMO	Lumos Pharma	$4.33	$16.50	281.06%	Buy
ACRV	Acrivon Therapeutics	$6.38	$21.83	242.16%	Buy
RZLT	Rezolute	$4.95	$13.50	172.73%	Buy
ANAB	AnaptysBio	$19.97	$52.00	160.39%	Buy
MLYS	Mineralys Therapeutics	$12.86	$30.00	133.28%	Buy
ADAG	Adagene	$2.22	$5.00	125.23%	Buy
APRE	Aprea Therapeutics	$3.02	$3.00	-0.66%	Buy
IKNA	Ikena Oncology	$1.68	$1.33	-20.83%	Buy

APRE Forecast FAQ

Is Aprea Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, Aprea Therapeutics (APRE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of APRE's total ratings.

What are Aprea Therapeutics's analysts' financial forecasts?

Aprea Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $525K (high $525K, low $525K), average EBITDA is $315K (high $315K, low $315K), average net income is $-11.896M (high $-11.204M, low $-12.588M), average SG&A $1.94M (high $1.94M, low $1.94M), and average EPS is $-2.003 (high $-1.886, low $-2.119). APRE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-11.583M (high $-11.583M, low $-11.583M), average SG&A $0 (high $0, low $0), and average EPS is $-1.95 (high $-1.95, low $-1.95).